复星医药(600196.SH)：控股子公司药品注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Kerry, has received acceptance from the National Medical Products Administration for the drug registration application of Brukinsa injection (project code: FKC889), aimed at treating relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) in adult patients [1] Group 1 - The drug is classified as a therapeutic biological product under category 3.2 [1] - The application is specifically for adult patients suffering from relapsed or refractory precursor B-cell acute lymphoblastic leukemia [1]